SLC9A1 and cancer: Cariporide, other potent NHE1 inhibitors of the Amiloride series, as well as powerful and selective NHE1 inhibitors of the non-Amiloride series, like Phx-3 and compound 9t, have the potential of being highly promising, minimally toxic and truly effective anticancer agents in a wide array of malignant tumours and leukaemias, hopefully representing a new paradigm in cancer therapeutics.